<!DOCTYPE html>
<html lang="en" class="no-js">
<head>
	<meta charset="UTF-8">
	<meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
	<title>Nature Reviews Cardiology Milestone Anticoagulants</title>

	<style>
		.js body {
			background-image: none;
		}

		.js #pixi-container {
			display: block;
		}

		@media screen and (max-width: 600px) {
			.js body {
				background-image: url("img/anticoagulants-cover-cells-final.jpg");
				background-size: cover;
			}

			.js #pixi-container {
				display: none;
			}
		}
	</style>
</head>
<body>

	<div id="pixi-container"></div>

	<section class="article-container stories">
		
		<ul>
			<li>
				<article id="milestone-1" class="story text-section milestone with-image" data-start="1916" data-end="1937" data-title="">

					<header class="header-flex-container">
						<p class="article-type">Milestone 1 <span class="date">(1916–1937)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.171">Discovery and purification of heparin</a>					
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-1.jpg" alt="Milestone 1: Discovery and purification of heparin">
						<p class="credit">Science Photo Library/Alamy Stock Photo</p>
					</section>
					
					<section class="text-flex-container">
						
						<p>Heparin was serendipitously discovered by Jay McLean and William Henry Howell working at Johns Hopkins Medical School; the anticoagulant was subsequently purified for clinical use by Charles Best and colleagues. <a href="https://www.nature.com/articles/nrcardio.2017.171">Read more</a>.</p>
						
						<ul class="author">
							<li>Gregory B. Lim</li>
						</ul>
					</section>
				</article>
			</li>

			<li>
				<article id="milestone-2" class="story text-section milestone with-image" data-start="1940" data-end="1978" data-title="">

					<header class="header-flex-container">
						<p class="article-type">Milestone 2 <span class="date">(1940–1978)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.172">Warfarin: from rat poison to clinical use</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-2.jpg" alt="Milestone 2: Warfarin: from rat poison to clinical use">
						<p class="credit">imageBROKER/Alamy Stock Photo</p>
					</section>

					<section class="text-flex-container">
						<p>Warfarin is a derivative of coumarin (a naturally occurring substance in sweet clover) that was developed by Karl Link and colleagues and originally marketed as a rodenticide, but subsequently adopted for clinical use as an anticoagulant. <a href="https://www.nature.com/articles/nrcardio.2017.172">Read more</a>.</p>
						
						<ul class="author">
							<li>Gregory B. Lim</li>
						</ul>
					</section>

					<article class="related-content video-section">
						<p class="article-type">Animation</p>

						<h2>The history of warfarin</h2>
						
						<div class="video-wrapper">
							<iframe width="560" height="315" src="https://www.youtube.com/embed/UVRkmPfkECE?rel=0&amp;controls=1&amp;showinfo=0" frameborder="0" allow="encrypted-media" allowfullscreen></iframe>
						</div>

						<p>This animation illustrates the history and development of warfarin, and its evolution from rat poison to widespread clinical anticoagulant drug.</p>
					</article>

				</article>
			</li>

			<li>
				<article id="milestone-3" class="story text-section milestone with-image" data-start="1947" data-end="1960">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 3 <span class="date">(1947–1960)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.173">Heparin and a VKA — a winning combination</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-3.jpg" alt="Milestone 3: Heparin and a VKA — a winning combination">
						<p class="credit">Shawn Hempel - Concepts/Alamy Stock Photo</p>
					</section>
	
					<section class="text-flex-container">
						<p>The combination of heparin and a vitamin K antagonist is found in randomized, controlled clinical trials to be an effective treatment for acute pulmonary embolism. <a href="https://www.nature.com/articles/nrcardio.2017.173">Read more</a>.</p>
						
						<ul class="author">
							<li>Conor A. Bradley</li>
						</ul>
					</section>
				</article>
			</li>

			<li>
				<article id="milestone-4" class="story text-section milestone with-image" data-start="1975" data-end="1978">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 4 <span class="date">(1975-1978)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.174">Low-dose heparin for VTE — prevention is better than cure</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-4.png" alt="Milestone 4: Low-dose heparin for VTE — prevention is better than cure">
						<p class="credit">L. Marshall/Macmillan Publishers Limited</p>
					</section>

					<section class="text-flex-container">
						<p>In a large series of clinical trials and meta-analyses, low doses of heparin are shown to be effective in reducing the incidence of postoperative venous thromboembolism. <a href="https://www.nature.com/articles/nrcardio.2017.174">Read more</a>.</p>
						
						<ul class="author">
							<li>Gregory B. Lim</li>
						</ul>
					</section>
	
				</article>
			</li>

			<li>
				<article id="milestone-5" class="story text-section milestone with-image" data-start="1979" data-end="1982">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 5 <span class="date">(1979–1982)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.175">High-dose heparin for secondary prevention</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-5.jpg" alt="Milestone 5: High-dose heparin for secondary prevention">
						<p class="credit">S. Fenwick/Macmillan Publishers Limited</p>
					</section>

					<section class="text-flex-container">
						<p>Low-dose heparin is found to be ineffective in preventing recurrent venous thrombosis, but higher doses are an effective alternative to warfarin for secondary prophylaxis. <a href="https://www.nature.com/articles/nrcardio.2017.175">Read more</a>.</p>
						
						<ul class="author">
							<li>Irene Fernández-Ruiz</li>
						</ul>
					</section>

				</article>

			</li>

			<li>
				<article id="milestone-6" class="story text-section milestone with-image" data-start="1983" data-end="1995">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 6 <span class="date">(1983–1995)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.176">Birth of the INR</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-6.jpg" alt="Milestone 6: Birth of the INR">
						<p class="credit">S. Fenwick/Macmillan Publishers Limited</p>
					</section>

					<section class="text-flex-container">
						<p>Control of vitamin K antagonists including warfarin is markedly improved by standardizing laboratory monitoring by replacing the prothrombin ratio with the international normalized ratio. <a href="https://www.nature.com/articles/nrcardio.2017.176">Read more</a>.</p>
						
						<ul class="author">
							<li>Karina Huynh</li>
						</ul>
					</section>

					<article class="related-content podcast-section">
						<header class="header-flex-container">
							<p class="article-type">Audio</p>

							<h2>Interview with Jack Hirsh</h2>


						</header>

						<section class="image-flex-container">
							<img src="img/audio/jack-hirsh.jpg" alt="Jack Hirsh">
						</section>

						<section class="text-flex-container">
							<p>Listen to Professor Jack Hirsh discuss his involvement in anticoagulant research, including the development of the international normalized ratio and low-molecular-weight heparins.</p>	
						</section>

						<section class="audio-flex-container">
							<audio controls preload="auto">
								Your browser does not support the <code>audio</code> element.
								<source src="audio/052017348-dreamy-ambient-electronic-music.ogg" type="audio/ogg"/>
								<source src="audio/052017348-dreamy-ambient-electronic-music.mp3" type="audio/mpeg"/>
							</audio>
						</section>
					</article>

				</article>
			</li>

			<li>
				<article id="milestone-7" class="story text-section milestone with-image" data-start="1996" data-end="1997">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 7 <span class="date">(1996-1997)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.177">A breakthrough for out-of-hospital treatment of thrombosis</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-7.jpg" alt="Milestone 7: A breakthrough for out-of-hospital treatment of thrombosis">
						<p class="credit">Science Photo Library/Alamy Stock Photo</p>
					</section>

					<section class="text-flex-container">
						<p>Studies show that low-molecular-weight heparin can be safely administered in a fixed or weight-adjusted dose without the need for monitoring, leading to convenient, out-of-hospital treatment of thrombosis. <a href="https://www.nature.com/articles/nrcardio.2017.177">Read more</a>.</p>
						
						<ul class="author">
							<li>Irene Fernández-Ruiz</li>
						</ul>
					</section>

					<article class="related-content podcast-section">
						<header class="header-flex-container">
							<p class="article-type">Audio</p>

							<h2>Interview with Harry Büller</h2>


						</header>

						<section class="image-flex-container">
							<img src="img/audio/harry-buller.jpg" alt="Harry Büller">
						</section>

						<section class="text-flex-container">
							<p>Listen to Professor Harry Büller discuss clinical trials on the prevention and treatment of thrombosis and how medical practice has evolved.</p>	
						</section>

						<section class="audio-flex-container">
							<audio controls preload="auto">
								Your browser does not support the <code>audio</code> element.
								<source src="audio/052017348-dreamy-ambient-electronic-music.ogg" type="audio/ogg"/>
								<source src="audio/052017348-dreamy-ambient-electronic-music.mp3" type="audio/mpeg"/>
							</audio>
						</section>
					</article>

				</article>
			</li>

			<li>
				<article id="milestone-8" class="story text-section milestone with-image" data-start="2001" data-end="2006">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 8 <span class="date">(2001-2006)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.178">Targeting the Xa factor</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-8.png" alt="Milestone 8: Targeting the Xa factor">
						<p class="credit">Alamy Stock Photo</p>
					</section>

					<section class="text-flex-container">
						<p>The demonstration that the synthetic pentasaccharide fondaparinux is effective for the prevention and treatment of venous thrombosis indicates that factor Xa is a good target for antithrombotic therapy. <a href="https://www.nature.com/articles/nrcardio.2017.178">Read more</a>.</p>
						
						<ul class="author">
							<li>Shimona Starling</li>
						</ul>
					</section>

					<article class="related-content video-section">
						<p class="article-type">Animation</p>

						<h2>Drug targets in the coagulation cascade</h2>

						<div class="video-wrapper">
							<iframe width="560" height="315" src="https://www.youtube.com/embed/YRZMdQOMPNQ?rel=0&amp;controls=1&amp;showinfo=0" frameborder="0" allow="encrypted-media" allowfullscreen></iframe>
						</div>

						<p>This animation illustrates the clotting factors involved in thrombus formation, and how these factors can be pharmacologically targeted using heparin, warfarin, and direct thrombin and factor Xa inhibitors for clinical anticoagulation.</p>
					</article>

					<article class="related-content text-section with-image">
						<header class="header-flex-container">
							<p class="article-type">Poster</p>

							<h2>Anticoagulant drugs</h2>
						</header>

						<section class="image-flex-container">
							<img src="img/posters/nrcar_anticoagulation.jpg" alt="The evolution of oral anticoagulants">
							<p class="credit">Macmillan Publishers Limited</p>
						</section>

						<section class="text-flex-container">
							<p>This poster displays the various classes of anticoagulant drugs that are used to prevent and treat venous and arterial thrombosis. <a href="https://www.nature.com/nrcardio/posters/anticoagulation/nrcar_anticoagulation_poster_web.pdf">Download the poster (3.2mb)</a>.</p>
						</section>
					</article>

				</article>
			</li>

			<li>
				<article id="milestone-9" class="story text-section milestone with-image" data-start="2003">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 9 <span class="date">(2003)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.179">Ximelagatran sets the stage for NOACs</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-9.jpg" alt="Milestone 9: Ximelagatran sets the stage for NOACs">
						<p class="credit">Brian Jackson/Alamy Stock Photo</p>
					</section>

					<section class="text-flex-container">
						<p>The development of ximelagatran provided the proof of principle that a specific oral thrombin inhibitor is safe and effective in a variety of thrombotic disorders, setting the stage for the introduction of a new class of oral thrombin and factor Xa inhibitors. <a href="https://www.nature.com/articles/nrcardio.2017.179">Read more</a>.</p>
						
						<ul class="author">
							<li>Megan Cully</li>
						</ul>
					</section>

				</article>
			</li>

			<li>
				<article id="milestone-10" class="story text-section milestone with-image" data-start="2007" data-end="2014">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 10 <span class="date">(2007–2014)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.180">Era of the NOACs</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-10.jpg" alt="Milestone 10: Era of the NOACs">
						<p class="credit">S.Fenwick/Macmillan Publishers Limited/Scott Camazine/Alamy Stock Photo</p>
					</section>

					<section class="text-flex-container">
						<p>Randomized trials with the direct thrombin and factor Xa inhibitors show that these non-vitamin K antagonist oral anticoagulants (NOACs) given in fixed doses are as safe and effective as warfarin in prevention and treatment of venous thromboembolism and in stroke prevention in atrial fibrillation. <a href="https://www.nature.com/articles/nrcardio.2017.180">Read more</a>.</p>
						
						<ul class="author">
							<li>Karina Huynh</li>
						</ul>
					</section>

					<article class="related-content text-section with-image">
						
						<header class="header-flex-container">
							<p class="article-type">Focus issue</p>
							
							<h2>
								<a href="https://www.nature.com/nrcardio/focus/anticoagulation-therapies/index.html">Anticoagulation therapies</a>
							</h2>
						</header>

						<section class="image-flex-container">
							<img src="img/focus-anticoagulation-therapies.jpg" alt="Anticoagulation therapies">
							<p class="credit">Cgtoolbox/Dreamstime.com</p>
						</section>

						<section class="text-flex-container">
							<p>This Focus issue features four Review articles in which experts discuss clinical trial data on oral direct thrombin and factor Xa inhibitors as alternatives to vitamin K antagonists in various clinical settings. <a href="https://www.nature.com/nrcardio/focus/anticoagulation-therapies/index.html">Read more</a>.</p>
							
						</section>
					</article>

				</article>
			</li>

			<li>
				<article id="milestone-11" class="story text-section milestone with-image" data-start="2011">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 11 <span class="date">(2011)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.181">Quest to find the optimal duration</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-11.jpg" alt="Milestone 11: Quest to find the optimal duration">
						<p class="credit">Andrey Sevostianov/Alamy Stock Photo</p>
					</section>

					<section class="text-flex-container">
						<p>A long-standing uncertainty in the field of anticoagulation is the optimal duration of treatment for venous thrombosis, and the careful balance between antithrombotic benefit and bleeding risk. <a href="https://www.nature.com/articles/nrcardio.2017.181">Read more</a>.</p>
						
						<ul class="author">
							<li>Karina Huynh</li>
						</ul>
					</section>

					<article class="related-content text-section with-image">
						
						<header class="header-flex-container">
							<p class="article-type">Review</p>
							
							<h2>
								<a href="https://www.nature.com/articles/nrcardio.2014.170">Balancing ischaemia and bleeding risks with novel oral anticoagulants</a>
							</h2>
						</header>

						<section class="image-flex-container">
							<img src="img/reviews/mehran.jpg" alt="Balancing ischaemia and bleeding risks with novel oral anticoagulants">
						</section>

						<section class="text-flex-container">
							<p>In this Review, Mehran and colleagues discuss the overall clinical effect of non-vitamin K antagonist oral anticoagulants, which is a balance between ischaemic benefit and bleeding risk. <a href="https://www.nature.com/articles/nrcardio.2014.170">Read more</a>.</p>

							<ul class="author">
								<li>Usman Baber, </li>
								<li>Ioannis Mastoris, </li>
								<li>& Roxana Mehran</li>
							</ul>
						</section>
							
					</article>
	
				</article>
			</li>

			<li>
				<article id="milestone-12" class="story text-section milestone with-image" data-start="2013">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 12 <span class="date">(2013)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.182">In search of better therapies to prevent device-induced thrombosis</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-12.jpg" alt="Milestone 12: In search of better therapies to prevent device-induced thrombosis">
						<p class="credit">S. Fenwick/Macmillan Publishers Limited</p>
					</section>

					<section class="text-flex-container">
						<p>The incidence of device-induced thrombosis (for example by catheters or cardiac prosthetic valves) highlights the need for more-targeted anticoagulants to prevent thrombosis on prosthetic surfaces. <a href="https://www.nature.com/articles/nrcardio.2017.182">Read more</a>.</p>
						
						<ul class="author">
							<li>Irene Fernández-Ruiz</li>
						</ul>
					</section>

					<article class="related-content podcast-section">
						<header class="header-flex-container">
							<p class="article-type">Audio</p>

							<h2>Interview with Jeffrey Weitz</h2>


						</header>

						<section class="image-flex-container">
							<img src="img/audio/jeff-weitz.jpg" alt="Jeffrey Weitz">
						</section>

						<section class="text-flex-container">
							<p>Listen to Profressor Jeffrey Weitz discuss the ongoing challenges in anticoagulant therapy and the developments that are on the horizon.</p>	
						</section>

						<section class="audio-flex-container">
							<audio controls preload="auto">
								Your browser does not support the <code>audio</code> element.
								<source src="audio/052017348-dreamy-ambient-electronic-music.ogg" type="audio/ogg"/>
								<source src="audio/052017348-dreamy-ambient-electronic-music.mp3" type="audio/mpeg"/>
							</audio>
						</section>
					</article>

				</article>
			</li>

			<li>
				<article id="milestone-13" class="story text-section milestone with-image" data-start="2015" data-end="2017">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 13 <span class="date">(2015-2017)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.183">Putting on the brakes: NOAC antidotes</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-13.jpg" alt="Milestone 13: Putting on the brakes: NOAC antidotes">
						<p class="credit">Laurel/Alamy Stock Photo</p>
					</section>

					<section class="text-flex-container">
						<p>Antidotes for the non-vitamin K antagonist oral anticoagulants (NOACs) are undergoing development and regulatory approval, and will allow rapid reversal of NOAC effects in emergency settings. <a href="https://www.nature.com/articles/nrcardio.2017.183">Read more</a>.</p>
						
						<ul class="author">
							<li>Megan Cully</li>
						</ul>
					</section>

					<article class="related-content text-section with-image">
						
						<header class="header-flex-container">
							<p class="article-type">Review</p>
							
							<h2>
								<a href="https://www.nature.com/articles/nrcardio.2017.223">Reversal agents for non-vitamin K antagonist oral anticoagulants</a>
							</h2>
						</header>

						<section class="image-flex-container">
							<img src="img/reviews/levy.jpg" alt="Reversal agents for non-vitamin K antagonist oral anticoagulants">
						</section>

						<section class="text-flex-container">

							<p>In this Review, Levy and colleagues describe the mechanism of action of the NOAC-reversal strategies, and provide guidance on potential indications and management strategies for reversal. <a href="https://www.nature.com/articles/nrcardio.2017.223">Read more</a>.</p>

							<ul class="author">
								<li>Jerrold H. Levy, </li>
								<li>James Douketis, </li>
								<li>& Jeffrey I. Weitz</li>
							</ul>
						</section>
							
					</article>

				</article>
			</li>

			<li>
				<article id="milestone-14" class="story text-section milestone with-image" data-start="2017">
					
					<header class="header-flex-container">
						<p class="article-type">Milestone 14 <span class="date">(2017)</span></p>
						
						<h2>
							<a href="https://www.nature.com/articles/nrcardio.2017.184">COMPASS-guided secondary prevention</a>
						</h2>
					</header>

					<section class="image-flex-container">
						<img src="img/milestones/milestone-14.png" alt="Milestone 14: COMPASS-guided secondary prevention">
						<p class="credit">V. Summersby/Macmillan Publishers Limited</p>
					</section>

					<section class="text-flex-container">
						<p>The COMPASS trial shows that the combination of low-dose rivaroxaban and aspirin is more effective than aspirin alone in reducing cardiovascular outcomes in patients with stable atherosclerotic vascular disease. <a href="https://www.nature.com/articles/nrcardio.2017.184">Read more</a>.</p>
						
						<ul class="author">
							<li>Gregory B. Lim</li>
						</ul>
					</section>

					<article class="related-content podcast-section">
						<header class="header-flex-container">
							<p class="article-type">Audio</p>

							<h2>Interview with John Eikelboom</h2>


						</header>

						<section class="image-flex-container">
							<img src="img/podcast.png" alt="Podcast placeholder">
							<p class="credit">Credit</p>
						</section>

						<section class="text-flex-container">
							<p>Listen to Professor John Eikelboom, lead investigator of the COMPASS trial, discuss the trial results, how the findings are likely to influence patient care, and the role of anticoagulants in the secondary prevention of cardiovascular disease.</p>	
						</section>

						<section class="audio-flex-container">
							<audio controls preload="auto">
								Your browser does not support the <code>audio</code> element.
								<source src="audio/052017348-dreamy-ambient-electronic-music.ogg" type="audio/ogg"/>
								<source src="audio/052017348-dreamy-ambient-electronic-music.mp3" type="audio/mpeg"/>
							</audio>
						</section>
					</article>

				</article>
			</li>

		</ul>
	</section>

	<form id="animation-control">
			<input type="checkbox" id="animations">
		<label for="animations">Background animation</label>
	</form>
	
	<div id="timeline-container">
		<div id="tooltip">
			<p id="tooltip-tag"></p>
			<p id="tooltip-title"></p>
		</div>
	</div>

</body>
</html>